Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
82°
Mostly Cloudy
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
Photos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Best of 2023
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Can-Fite BioPharma Ltd.
< Previous
1
2
3
Next >
Can-Fite Reports Third Quarter 2022 Financial Results & Provides Clinical Update
November 25, 2022
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Tickers
CANF
Can-Fite: Positive New Data from it’s Phase III Psoriasis Study will be Presented Today at an Industry Expert Summit in Boston
November 02, 2022
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Tickers
CANF
Can-Fite: Findings Showing the Complete Clearance of Cancer in Patient Treated With Namodenoson Will Be Presented at the AASLD Liver Meeting®
October 25, 2022
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Tickers
CANF
Can-Fite to Present its Phase IIb NASH Drug Candidate Namodenoson at Upcoming Conference
October 13, 2022
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Tickers
CANF
Can-Fite: New Phase III Psoriasis Data Showing Superior Safety & Improved Efficacy Presented by KOL Dr. Papp at the 31st European Academy of Dermatology
September 12, 2022
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Tickers
CANF
Can-Fite Reports Second Quarter 2022 Financial Results & Provides Clinical Update
August 25, 2022
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Tickers
CANF
Can-Fite’s Drug Namodenoson Approved for Compassionate Use Treatment of Advanced Liver Cancer Patients in Romania
August 23, 2022
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Tickers
CANF
Can-Fite: Reports Progress in the Development of Piclidenoson for Osteoarthritis in Pets Through its Partner Vetbiolix
August 17, 2022
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Tickers
CANF
Can-Fite Selected to Present the Positive Psoriasis Phase III Data at the 31st European Academy of Dermatology and Venerology Congress
August 22, 2022
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Tickers
CANF
Can-Fite to Submit FDA & EMA Registration Plans for Piclidenoson in the Oral Treatment of Moderate to Severe Psoriasis
July 11, 2022
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Tickers
CANF
Can-Fite Announces Positive Top-Line Results from Piclidenoson Phase III COMFORT™ Study in Moderate to Severe Psoriasis
June 29, 2022
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Tickers
CANF
Can-Fite’s CF602 Reverses Erectile Dysfunction in Diabetic Pre-clinical Model: Study Published in Peer-Reviewed Journal Andrologia
June 24, 2022
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Tickers
CANF
Can-Fite Announces Publication of Clinical Study Data for Piclidenoson and Namodenoson in Scientific Journal
June 09, 2022
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Tickers
CANF
Can-Fite Reports First Quarter 2022 Financial Results & Provides Clinical Update
May 26, 2022
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Tickers
CANF
Can-Fite Granted Key NASH Patent in Israel
May 16, 2022
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Tickers
CANF
Can-Fite’s CEO to Present Namodenoson’s Efficacy in Liver Cancer as Expert Speaker at the Adenosine Pathway Targeted Cancer Immunotherapy Summit
May 02, 2022
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Tickers
CANF
Can-Fite is Developing a Topical Piclidenoson Psoriasis Treatment that Shows Efficacy in a Preclinical Model: Potential Complementary Product to its Phase III Oral Psoriasis Drug
April 05, 2022
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Tickers
CANF
Can-Fite to Present at Dermatology Drug Development Summit Europe on April 6, 2022
March 28, 2022
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Tickers
CANF
Can-Fite Reports 2021 Financial Results & Provides Clinical Update
March 24, 2022
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Tickers
CANF
Can-Fite: Namodenoson’s Treatment of Liver Fibrosis Receives Notice of Allowance from U.S. Patent Office
March 14, 2022
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Tickers
CANF
Can Fite Announces First Patient Enrolled in Phase IIb NASH Clinical Trial with Namodenoson
January 31, 2022
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Tickers
CANF
Prior to Phase III Psoriasis Data Release Can Fite Reports that Piclidenoson Destroys Pathological Skin Cells in vitro
January 13, 2022
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Tickers
CANF
Can-Fite to Conduct Investor Meetings during the J.P. Morgan Healthcare Conference
January 10, 2022
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Tickers
CANF
Can-Fite Issues Letter to Shareholders
January 05, 2022
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Tickers
CANF
Following Complete Clearance of Cancer Lesions in Advanced Liver Cancer Patient, Can-Fite is Filing Patent Applications for the Treatment of Various Advanced Solid Tumors
December 29, 2021
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Tickers
CANF
Liver Cancer Patient Treated with Can-Fite’s Namodenoson Clears All Cancer Lesions Under Open Label Extension of Phase II Study
December 20, 2021
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Tickers
CANF
Can-Fite’s Phase III Psoriasis Study to Complete 16-Week Treatment of Last Patient in January; Topline Data Expected Q1 2022
December 07, 2021
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Tickers
CANF
Can-Fite CEO Dr. Pnina Fishman to be Guest Speaker at 5th Annual NASH Summit 2021
November 24, 2021
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Tickers
CANF
Can-Fite’s Piclidenoson Commences Clinical Study for the Treatment of Canine Osteoarthritis
November 23, 2021
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Tickers
CANF
Can-Fite to Present at H.C. Wainwright 7th Annual Israel Conference
November 12, 2021
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Tickers
CANF
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.